BridgeBio Pharma reported $194.5 million in total revenue for Q1 2026, driven mainly by $180.6 million from U.S. sales of Attruby, its treatment for transthyretin amyloid cardiomyopathy. The company highlighted strong commercial momentum, including recent approval of Attruby in Brazil and positive real-world data showing its benefits. BridgeBio also submitted its first NDA for BBP-418 in LGMD2I/R9 and plans to file NDAs for encaleret in ADH1 and infigratinib in achondroplasia later this year, with all three potentially eligible for priority review. Additionally, the company announced a $500 million share repurchase program, reflecting confidence in its valuation and future growth prospects.
